Evidence map›Paper›PMID 36983885›Full record

ReviewLife (Basel, Switzerland)2023

Biomarkers of Osteoarthritis-A Narrative Review on Causal Links with Metabolic Syndrome.

Samuel James Lynskey, Marc Julian Macaluso, Stephen D Gill, Sean L McGee, Richard S Page

Abstract readReview
In one paragraph

Review in Life (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. METTL3 Regulates the mCartilage · 2025
    Article
  10. Review
  11. Observational
  12. Review
  13. Osteoarthritis and cartilage open · 2024
    Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Samuel James LynskeyDepartment of Orthopaedic Surgery, Geelong University Hospital, Geelong, VIC 3220, Australia.ORCID 0000-0003-0946-4613
Marc Julian MacalusoSchool of Medicine, Faculty of Health, Deakin University, Waurn Ponds, Geelong, VIC 3216, Australia.
Stephen D GillDepartment of Orthopaedic Surgery, Geelong University Hospital, Geelong, VIC 3220, Australia.ORCID 0000-0001-8722-0572
Sean L McGeeSchool of Medicine, Faculty of Health, Deakin University, Waurn Ponds, Geelong, VIC 3216, Australia.
Richard S PageDepartment of Orthopaedic Surgery, Geelong University Hospital, Geelong, VIC 3220, Australia.ORCID 0000-0002-2225-7144

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Development of OA (OA) is multifactorial and is strongly associated with risk factors such as aging, trauma, metabolic disorders, and obesity. Metabolic Syndrome (MetS)-associated OA, collectively coined MetS-OA, is an increasingly recognized entity in which metabolic disorders and low-grade inflammation play a key mechanistic role in the disruption of joint homeostasis and cartilage degradation. Although there have been enormous efforts to discover biomarkers of MetS and OA, studies investigating a pathophysiological link between MetS and OA are relatively limited, and no serum blood marker has proved diagnostic so far. OA biomarkers that are necessary to discriminate and diagnose early disease remain to be elicited, explained in part by limited prospective studies, and therefore limited tools available to utilize in any prognostic capacity. Biomarker validation projects have been established by the Biomarker Consortium to determine biochemical markers demonstrating predictive validity for knee OA. Given that the metabolic constituents of MetS are treatable to varying extents, it stands to reason that treating these, and monitoring such treatment, may help to mitigate deleterious links with OA development. This narrative review will describe the current state of biomarker identification and utility in OA associated with MetS. We discuss the pathophysiological mechanisms of disease according to constituent pathologies of MetS and how identification of biomarkers may guide future investigation of novel targets.

Indexed as

metabolic syndromeMetabolic Syndrome associated OAMetS-OAomicsosteoarthritistranscriptomics

Identifiers

PMID36983885
PMCPMC10051744

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.